Synergistic Interactions of SARs-CoV2 and environmental toxicants in Experimental Parkinsonism
SARs-CoV2 与环境毒物在实验性帕金森病中的协同相互作用
基本信息
- 批准号:10316307
- 负责人:
- 金额:$ 42.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-01 至 2022-12-31
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVACE2AcuteAddressAffectAgeusiaAnosmiaAutopsyBasal GangliaBiological AssayBloodBrainCOVID-19Cell DeathCellsCerebrovascular systemCessation of lifeClinicalConfusionDiarrheaDiseaseDoseEncephalopathiesEnteric Nervous SystemExperimental ParkinsonismHeadacheHumanImmuneInfectionInflammationInflammatory ResponseInfluenzaInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H5N1 SubtypeK-18 conjugateMapsMethodsMicrospheresModelingMusNervous system structureNeurologicNeuronsNeurotropismPainParaquatParkinson DiseaseParkinsonian DisordersPathologyPeripheralPopulationProcessProteinsRNAReportingRespiratory Tract InfectionsRiskRotenoneSARS-CoV-2 infectionSecondary toSeizuresSignal TransductionSurvivorsSymptomatic ParkinsonismSymptomsSyndromeSystemTherapeutic InterventionTimeToxic Environmental SubstancesTropismVaccinesViralViral Respiratory Tract InfectionVirusVirus DiseasesWestern Equine Encephalitis VirusWild Type Mousealpha synucleinastrogliosiscerebrovascularcytokinecytokine release syndromedopaminergic neuronenvironmental agentexperienceexperimental studyimmunogenicnervous system disordernervous system infectionneuroinflammationneuron lossneurotropicpandemic diseaseparticlepreclinical studyreceptorreceptor bindingrespiratory virusresponse
项目摘要
ABSTRACT
Approximately16.5 million people have been infected with the SARS-CoV2 virus with approximately 650,000 (and
rising) deaths. While primarily a respiratory virus, clinical observations appear to demonstrate nervous system
involvement. These include those associated with the CNS (headache, confusion, seizure, stoke), PNS (pain, anosmia,
ageusia) and enteric nervous systems (ENS, diarrhea). What is not fully understood- at this time- is how the SARS-CoV2
virus produces these nervous system disorders. We also do not know if the impact(s) on the nervous system will persist,
or possibly even become apparent, post infection. Previous studies in my lab examining neurotropic (H5N1 influenza,
western equine encephalitic virus) and non-neurotropic (pandemic H1N1 influenza) have shown that each can produce
immediate and/or delayed effects in the CNS, including induction of pathologies seen in Parkinson’s disease. Related to
SARs-CoV2, a number of recent studies, using autopsy material has examined the localization of SARS-CoV-2 virus in
the brain. From these studies, approximately 36% had apparently low levels of viral SARS-CoV-2 RNA and protein in
brain, although in each of these studies a complete cellular and localization map have not been reported. Also, it is not
known if the viral particles found in the CNS were present intracellularly due to inherent neurotropism or were only
present in the CNS due to breaches in the cerebral vasculature. (i.e., secondary to cerebrovascular damage). Even without
neurotropism, an understanding of changes in the nervous system are critical since it is that any immediate and/or delayed
effects may result from dysfunctional signals (peripheral cytokine storms) that arise outside of the nervous system; yet
impact the function and, perhaps, survival of neurons. To address these unanswered questions, two specific aims are
proposed. In Specific Aim 1, we will empirically determine the neurotropic potential of the SARS-CoV2 virus
(USA-WA1) throughout its natural period of infection in the CNS, PNS and ENS in C57BL/6J mice and C57BL/6J
mice expressing a human ACE2 receptor (K18-hACE2, B6.Cg-Tg(K18-ACE2)2Prlmn/J). We will also examine the
induced inflammatory response in the periphery and brain. In Specific Aim 2, we will determine if resolved SARS-
CoV2 infection can sensitize SNpc DA neurons to agents that have been shown to induce parkinsonism (paraquat
and rotenone) in mice and humans as well as if it can exacerbate the spread and extent of alpha-synuclein
pathology. These aims and associated experiments will allow us to directly determine the neurotropic and immunogenic
potential of SARS-CoV2. They will also allow us to determine this virus has the potential to sensitize neurons to
exogenous insults as has been demonstrated with some other respiratory viruses. Understanding if this pandemic virus
affects the CNS and in particular, the basal ganglia is important for both short term treatment as well as longer-term
management of post infection effects. Additionally, understanding the neuropathological sequalae of SARS-CoV2 on the
nervous system will be necessary for later studies examining if a therapeutic intervention (i.e. vaccine or modulator of
inflammatory response) can protect against primary and/or secondary nervous system effects of this respiratory infection.
摘要
大约有1650万人感染了SARS-CoV 2病毒,其中大约65万人(
上升)死亡。虽然主要是呼吸道病毒,但临床观察似乎表明神经系统
参与。这些包括与CNS(头痛、意识模糊、癫痫发作、斯托克)、PNS(疼痛、嗅觉丧失,
味觉丧失)和肠神经系统(ENS,腹泻)。目前尚不完全清楚的是,SARS-CoV 2
病毒导致这些神经系统紊乱。我们也不知道对神经系统的影响是否会持续下去,
甚至可能在感染后变得明显我实验室以前的研究检查嗜神经性(H5 N1流感,
西方马脑炎病毒)和非嗜神经性(大流行性H1N1流感)已经表明,每一种都可以产生
CNS中的即时和/或延迟效应,包括诱导帕金森病中观察到的病理。有关
SARS-CoV-2,最近的一些研究,使用尸检材料检查了SARS-CoV-2病毒在
大脑从这些研究中,大约36%的人的病毒SARS-CoV-2 RNA和蛋白水平明显较低,
脑,虽然在这些研究中的每一个完整的细胞和定位图还没有被报道。而且,
已知在CNS中发现的病毒颗粒是否由于固有的嗜神经性而存在于细胞内,或仅存在于细胞内。
由于脑血管系统中的破坏而存在于CNS中。(i.e.,继发于脑血管损伤)。即使没有
向神经性,了解神经系统的变化是至关重要的,因为它是任何立即和/或延迟
影响可能是由神经系统外部产生的功能失调信号(外周细胞因子风暴)引起的;然而
影响神经元的功能和存活。为了解决这些悬而未决的问题,有两个具体目标:
提出了在具体目标1中,我们将根据经验确定SARS-CoV 2病毒的神经营养潜力
(USA-WA 1)在C57 BL/6 J小鼠和C57 BL/6 J小鼠的CNS、PNS和ENS中的整个自然感染期内,
表达人ACE 2受体(K18-hACE 2,B6.Cg-Tg(K18-ACE 2)2 Prlmn/J)的小鼠。我们亦会研究
在外周和大脑中引起炎症反应。在具体目标2中,我们将确定是否解决了SARS-
CoV 2感染可使SNpc DA神经元对已显示诱导帕金森综合征的药剂(百草枯)敏感
和鱼藤酮),以及它是否会加剧α-突触核蛋白的传播和程度
病理这些目标和相关的实验将使我们能够直接确定亲神经性和免疫原性
SARS-CoV 2的潜力他们还将使我们能够确定这种病毒有可能使神经元敏感,
外源性损伤,如已经用一些其它呼吸道病毒证明的。了解这种流行性病毒
影响CNS,特别是基底神经节对于短期治疗和长期治疗都很重要
管理感染后的影响。此外,了解SARS-CoV 2在大脑中的神经病理学后遗症
神经系统将是必要的,为以后的研究,检查是否有治疗性干预(即疫苗或调节剂,
炎症反应)可以保护免受这种呼吸道感染的原发性和/或继发性神经系统影响。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
COVID-19 Infection Enhances Susceptibility to Oxidative Stress-Induced Parkinsonism.
- DOI:10.1002/mds.29116
- 发表时间:2022-07
- 期刊:
- 影响因子:8.6
- 作者:Smeyne, Richard J.;Eells, Jeffrey B.;Chatterjee, Debotri;Byrne, Matthew;Akula, Shaw M.;Sriramula, Srinivas;O'Rourke, Dorcas P.;Schmidt, Peter
- 通讯作者:Schmidt, Peter
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RICHARD J SMEYNE其他文献
RICHARD J SMEYNE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RICHARD J SMEYNE', 18)}}的其他基金
Role of pathogenic Parkinsonian mutations in the seeding and propagation of alpha-synuclein in the CNS
致病性帕金森病突变在中枢神经系统中α-突触核蛋白播种和传播中的作用
- 批准号:
9764564 - 财政年份:2019
- 资助金额:
$ 42.9万 - 项目类别:
Role of pathogenic Parkinsonian mutations in the seeding and propagation of alpha-synuclein in the CNS
致病性帕金森病突变在中枢神经系统中α-突触核蛋白播种和传播中的作用
- 批准号:
10599135 - 财政年份:2019
- 资助金额:
$ 42.9万 - 项目类别:
Role of pathogenic Parkinsonian mutations in the seeding and propagation of alpha-synuclein in the CNS
致病性帕金森病突变在中枢神经系统中α-突触核蛋白播种和传播中的作用
- 批准号:
10382329 - 财政年份:2019
- 资助金额:
$ 42.9万 - 项目类别:
H5N1 Influenza Virus as a Novel Etiological Agent in Parkinsons Disease
H5N1 流感病毒作为帕金森病的新病原体
- 批准号:
7825434 - 财政年份:2009
- 资助金额:
$ 42.9万 - 项目类别:
相似国自然基金
新型蝙蝠MERS簇冠状病毒HKU5的ACE2细胞受体识别及其分子机制研究
- 批准号:
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
铁皮石斛通过肠道 ACE2 修复 Trp/GPR142 介
导“肠-胰岛 ”轴血糖调控功能的降糖机制研
究
- 批准号:Y24H280055
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
人类ACE2变构抑制剂的成药性及其抗广谱冠状病毒感染的机制研究
- 批准号:82330111
- 批准年份:2023
- 资助金额:220 万元
- 项目类别:重点项目
CAFs来源的外泌体负性调控ACE2促进肾透明细胞癌癌栓新辅助靶向耐药的机制研究
- 批准号:82373169
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
新型蝙蝠MERS簇冠状病毒HKU5的ACE2受体识别及细胞入侵机制研究
- 批准号:32300137
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于AT2/ACE2/Ang(1-7)/MAS轴调控心脏-血管-血液系统性重构演变规律研究心衰气虚血瘀证及其益气通脉活血化瘀治法生物学基础
- 批准号:82305216
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于外泌体miRNAs介导细胞通讯的大豆ACE2激活肽调控血管稳态机制研究
- 批准号:32302080
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
感毒清经ACE2/Ang(1-7)/MasR信号通路抑制PM2.5诱导慢性气道炎症的机制:聚焦肺泡巨噬细胞极化与“胞葬”的表型串扰
- 批准号:82305171
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
刺参自溶引发机制中ACE2调控靶点的调控网络研究
- 批准号:32372399
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
Spike变异对新冠病毒抗原性及ACE2种属嗜性的影响研究
- 批准号:82272305
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
相似海外基金
新型コロナウイルス感染阻害能を有する抗ACE2抗体の阻害機構に関する構造基盤解明
阐明具有抑制新型冠状病毒感染能力的抗ACE2抗体抑制机制的结构基础
- 批准号:
24K09338 - 财政年份:2024
- 资助金额:
$ 42.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
ACE2のユビキチン化を介したコロナウイルス感染機構の解明と創薬への挑戦
通过ACE2泛素化阐明冠状病毒感染机制和药物发现的挑战
- 批准号:
22KJ2499 - 财政年份:2023
- 资助金额:
$ 42.9万 - 项目类别:
Grant-in-Aid for JSPS Fellows
ACE2阻害薬およびERK経路阻害薬による慢性腎炎進展抑制効果の検証
ACE2抑制剂和ERK通路抑制剂抑制慢性肾炎进展的效果验证
- 批准号:
23K14982 - 财政年份:2023
- 资助金额:
$ 42.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Large-scale compatibility assessments between ACE2 proteins and diverse sarbecovirus spikes
ACE2 蛋白和多种 sarbecovirus 尖峰之间的大规模兼容性评估
- 批准号:
10722852 - 财政年份:2023
- 资助金额:
$ 42.9万 - 项目类别:
一次線毛とコロナウイルス感染におけるACE2の役割の解明
阐明 ACE2 在原发菌毛和冠状病毒感染中的作用
- 批准号:
22KF0004 - 财政年份:2023
- 资助金额:
$ 42.9万 - 项目类别:
Grant-in-Aid for JSPS Fellows
The regulatory roles of ACE2 and its interaction with Nrf2 in arsenic-induced endothelial dysfunction in experimental and epidemiological studies
实验和流行病学研究中 ACE2 的调节作用及其与 Nrf2 的相互作用在砷诱导的内皮功能障碍中的作用
- 批准号:
23K16310 - 财政年份:2023
- 资助金额:
$ 42.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Role of ACE2 in the mechanism of intestinal regeneration
ACE2在肠道再生机制中的作用
- 批准号:
23K15078 - 财政年份:2023
- 资助金额:
$ 42.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Research and development of a novel pediatric anti-obesity medicine via ACE2 activation in DIZE
通过 DIZE 中 ACE2 激活研发新型儿科抗肥胖药物
- 批准号:
23K15417 - 财政年份:2023
- 资助金额:
$ 42.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Lung delivery of novel ACE2 variants for COVID-19
针对 COVID-19 的新型 ACE2 变体的肺部输送
- 批准号:
10483042 - 财政年份:2022
- 资助金额:
$ 42.9万 - 项目类别:
ACE2 on gut barrier dysfunction and BRB disruption
ACE2 对肠道屏障功能障碍和 BRB 破坏的影响
- 批准号:
10535485 - 财政年份:2022
- 资助金额:
$ 42.9万 - 项目类别: